[Effect of ACNU against experimental XXXX --immunohistochemical study using anti-BrdU monoclonal antibody].

@entity1603 @entity1313 @entity5 @entity35 @entity6962
We have studied the efficacy of intrathecal ACNU against experimental @entity5 . In the present report, the effect of ACNU on the growth kinetics of the @entity5 was evaluated by the immunohistochemical technique using anti-BrdU monoclonal antibody. The experimental @entity5 was developed by inoculation of Walker 256 @entity6962 cells into the cisterna magna of @entity35 . Seven days after the inoculation of @entity5 cells, the animals were treated either by intravenous (15 mg/kg) or intrathecal (1.5 mg/kg) ACNU. Four, 12, 24, 48, 96 or 144 hours after treatment, the animals received intravenous @entity1603 (200 mg/kg). Thirty minutes thereafter, they were sacrificed and the brain was removed. L. I. was calculated by counting the immunoreactive @entity5 cells. L. I. of the @entity5 without treatment on the seventh day after inoculation was over 40%. L. I. began to decrease 24 hours after intravenous ACNU, and remained 11% up to 96 hours. On the other hand, L. I. already decreased to 20% 4 hours after intrathecal ACNU and remained to be low (17%) up to 48 hours. However, L. I. increased to 38% at 96 hours. Thus, the effect on the growth kinetics of the @entity5 differs between intravenous and intrathecal ACNU. These results are considered to be useful informations for determining the optimal dosage of the antineoplastic agent against the @entity1313 and developing the effective combination chemotherapy.
